The International Coalition of Medicines Regulatory Authorities (ICMRA) has published a statement on the continuation of clinical trials.
Swissmedic was involved in drafting this ICMRA statement: it is in favour of continuing clinical trials of Covid-19 vaccines in order to obtain critical data and for as long as this is feasible. Continuing clinical trials after a regulatory decision may, among other things, give rise to important findings regarding long-term safety and efficacy – including among specific subgroups.
The statement is directed at all interest groups, vaccinated persons, researchers, universities, regulatory authorities and the pharmaceutical industry.
The complete statement (in English) is available at: